INVA Q1 2024 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M+1.5% YoY

Gross Profit

$67M85.8% margin

Operating Income

$26M33.3% margin

Net Income

$37M47.1% margin

EPS (Diluted)

$0.46

QoQ Revenue Growth

-9.7%

Cash Flow

Operating Cash Flow

$37M

Free Cash Flow

$37M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$564M

Stockholders' Equity

$704M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$76M	+1.5%
Gross Profit	$67M	$53M	+24.5%
Operating Income	$26M	$21M	+22.2%
Net Income	$37M	$35M	+4.8%

Revenue Segments

Royalty

$58M75%

Product

$19M25%